Anti-Human Polyoma virus JCV capsid protein VP1 antibody [8E8] (ab34756)
Key features and details
- Mouse monoclonal [8E8] to Human Polyoma virus JCV capsid protein VP1
- Suitable for: Indirect ELISA, WB
- Isotype: IgG2a
Overview
-
Product name
Anti-Human Polyoma virus JCV capsid protein VP1 antibody [8E8] -
Description
Mouse monoclonal [8E8] to Human Polyoma virus JCV capsid protein VP1 -
Host species
Mouse -
Tested applications
Suitable for: Indirect ELISA, WBmore details -
Species reactivity
Reacts with: Other species -
Immunogen
Recombinant full length protein corresponding to Human Polyoma virus JCV capsid protein VP1. Recombinant full length purified major capsid protein VP1 of human polyomavirus JCV expressed in yeast S.cerevisiae.
-
General notes
This product was changed from ascites to tissue culture supernatant on 28/11/2017. Lot numbers higher than GR48370-3, GR185137-5, GR185137-7 and GR185137-8 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
8E8 -
Myeloma
Sp2/0 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab34756 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Indirect ELISA |
1/1000 - 1/10000.
|
|
WB |
1/1000 - 1/5000.
|
Notes |
---|
Indirect ELISA
1/1000 - 1/10000. |
WB
1/1000 - 1/5000. |
Target
-
Relevance
The human polyomavirus JC virus (JCV) infects greater than 80% of the human population. The JC virus is a small (38-40 nm in diameter) double stranded, circular DNA virus covered by an icosahedral capsid. Infection with JCV is asymptomatic and it occurs in early childhood. After the primary infection, the virus remains in latent state in the kidney, until it's reactivation under immunosuppressive conditions to result in Progressive Multifocal Leukoencephalopathy (PML), a fatal demyelinating disease. 70% of all HIV-1- infected patients will exhibit neurological disorders and between 5 and 8% of all HIV-1-infected patients will develop PML. Similar to other polyomaviruses, JCV can cause tumors when intracerebrally inoculated at high titers into developing rodent. Several reports suggest the association of viruses, especially of the polyomavirus family with different types of human brain tumors. Tumorigenecity of JCV is most likely induced by the viral early gene product T-antigen. T-antigen has the capacity to interact with several tumor suppressor proteins, most notably p53, and functionally inactivate these proteins. -
Database links
- Entrez Gene: 2828425 Other species
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab34756 has been referenced in 12 publications.
- Scribano S et al. Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples. J Clin Virol 128:104435 (2020). PubMed: 32442760
- Wilczek MP et al. JC Polyomavirus Infection Reveals Delayed Progression of the Infectious Cycle in Normal Human Astrocytes. J Virol 94:N/A (2020). PubMed: 31826993
- Querido S et al. High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first evidence of JC virus as a potential oncovirus in bladder cancer. Am J Transplant 20:1188-1191 (2020). PubMed: 31654479
- Reoma LB et al. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol 86:878-884 (2019). PubMed: 31600832
- DuShane JK et al. High-Throughput Characterization of Viral and Cellular Protein Expression Patterns During JC Polyomavirus Infection. Front Microbiol 10:783 (2019). PubMed: 31065251